Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine…
By C. Blanke, C. Rankin, G. Demetri, C. Ryan, M. von Mehren, R. Benjamin, A. Raymond, V. Bramwell, L. Baker, R. Maki and 6 more. Journal of Clinical Oncology, 2008
1,004 citations recorded by the source corpus.
Subfields: Gastroenterology, Surgery
View Paper: https://www.semanticscholar.org/paper/5dc904077ac445d6f37ee8e97535cbd39c13cdb5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Surgery
Citations in the corpus
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, methodology): “Other clinical trials were performed to assess the efficacy of Imatinib against c-KIT and PDGF receptor in patients affected by advanced and/or metastatic GIST tumor showing a good response rate and consequently an increased overall survival (OS) (Dagher et al., 2002; Blanke et al., 2008).”
- Gastrointestinal stromal tumours: origin and molecular oncology (2011, background): “Overall, imatinib achieved disease control in 70–85% of patients with advanced KIT-positive GISTs, and the median progression-free survival was 20–24 month”
- Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. (2011, background): “Similarly, one phase III study of imatinib in GIST showed that 33% of patients who experienced progression on 400 mg of imatinib experienced a second response and/or disease stabilization when the dose was increased to 800 mg.(93) Dose escalation might also be an ▪ TABLe 2 - exemplary mechanisms of ”